|Articles|August 1, 2001

Pharmaceutical Executive

  • Pharmaceutical Executive-08-01-2001
  • Volume 0
  • Issue 0

Science-Driven Marketing

That marketing should begin early in product development has become a truism in the pharma industry. But as a statement on its own, it sheds little light. What does it mean to begin? At what point do marketers insert themselves into the process? To what end do they enter where once only scientists trod? And, the ultimate question—which the truism fails to answer—how might their intrusion affect the lives of patients, in trial or thereafter?

Articles in this issue

about 25 years ago

Decision Making at Digital Speed

about 25 years ago

Mergers: Big Pharma Shrinks Some

about 25 years ago

Generics: Streamline and Stimulate

about 25 years ago

Grace Under Fire

about 25 years ago

Get Ready to Merge or Diverge

about 25 years ago

Pharma's Quantum Shuffle

Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.